ATLANTA, GA – – (Newsfile Corp. – January 25, 2021) – – Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (“Neoleukin” or the “Company”) (NASDAQ: NLTX) complied with federal securities laws. On January 8, 2021, Neoleukin announced that “on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.” The price of Neoleukin’s stock fell following the announcement. If you purchased shares of Neoleukin and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights or at www.holzerlaw.com.